English
Regional settings| Spread | 0.51 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 45.83 |
| Open | 45.48 |
| 1-Year Change | 44.66% |
| Day's Range | 45.48 - 46.25 |
Vericel Corporation is a commercial-stage biopharmaceutical company. The Company specializes in cell therapies and specialty biologics for the sports medicine and severe burn care. It operates in one reportable segment, the research, product development, manufacture, and distribution of cellular therapies for use in the treatment of specific diseases. It markets two autologous cell therapy products in the United States, which includes MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA).
BRIEF: For the fiscal year ended 31 December 2021, Vericel Corp revenues increased 26% to $156.2M. Net loss totaled $7.5M vs. income of $2.9M. Revenues reflect MACI segment increase of 18% to $111.6M, Epicel segment increase of 51% to $41.5M. Net loss reflects Stock-based Compensation in SGA increase from $10M to $26.5M (expense), Other Selling , General Expense increase of 21% to $71.1M (expense).
Common Stock no Par, 3/11, 62.5M auth., 38,618,037 issd. Insiders control approx. 0.63%. IPO: 2/97, 3M shares @ $7 byCowen & Company. 02/10 1-for-8 reverse split. 10/13, 1-for-20 Reverse Stock split.
